AJPH
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

American Journal of Public Health, Vol. 81, Issue 1 90-96, Copyright © 1991 by American Public Health Association

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gerstman, B B
Right arrow Articles by Stadel, B V
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gerstman, B B
Right arrow Articles by Stadel, B V
Trends in the content and use of oral contraceptives in the United States, 1964-88.

B B Gerstman, T P Gross, D L Kennedy, R C Bennett, D K Tomita and B V Stadel

Office of Epidemiology and Biostatistics, Food and Drug Administration, Rockville, MD 20857.

Drug marketing and physician survey data were used to examine trends in the use and hormonal content of oral contraceptives in the United States between 1964 and 1988. Retail prescriptions for oral contraceptives peaked at approximately 68 million in 1973 and have remained between 50 million and 60 million since 1981. Despite this relative consistency in the number of prescriptions, physician "mentions" of oral contraceptives have increased by approximately 75 percent. This increase may reflect closer monitoring of women on oral contraceptives. Use of multiphasic formulations has steadily risen, accounting for 37 percent of the oral contraceptive prescriptions in 1988. Mean estrogen and progestin doses in all types of formulations have steadily declined. A change in the type of estrogen and progestin used in preparations has coincided with this decline in dose. The association between age and use of high-dose formulations seen in the past was no longer evident in 1988. The data demonstrate that oral contraceptive formulations in wide use today differ in hormone content from those of the past, when most of the major studies addressing the risks associated with oral contraceptive use were completed. There is therefore a need to determine the risks and long-term effects associated with these newer formulations.




This article has been cited by other articles:


Home page
 Obstet GynecolHome page
G. Lurie, P. Thompson, K. E. McDuffie, M. E. Carney, K. Y. Terada, and M. T. Goodman
Association of Estrogen and Progestin Potency of Oral Contraceptives With Ovarian Carcinoma Risk
Obstet. Gynecol., March 1, 2007; 109(3): 597 - 607.
[Abstract] [Full Text] [PDF]

Home page
 Obstet GynecolHome page
J. B. Greer, F. Modugno, G. O. Allen, and R. B. Ness
Androgenic Progestins in Oral Contraceptives and the Risk of Epithelial Ovarian Cancer
Obstet. Gynecol., April 1, 2005; 105(4): 731 - 740.
[Abstract] [Full Text] [PDF]

Home page
 Obstet GynecolHome page
V. L. Holt, K. L. Cushing-Haugen, and J. R. Daling
Body Weight and Risk of Oral Contraceptive Failure
Obstet. Gynecol., May 1, 2002; 99(5): 820 - 827.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
L. Rosenberg, J. R. Palmer, R. S. Rao, and S. Shapiro
Low-Dose Oral Contraceptive Use and the Risk of Myocardial Infarction
Arch Intern Med, April 23, 2001; 161(8): 1065 - 1070.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1991 by the American Public Health Association